• Company
• What are the chances of Dovprela's successful benefits?
• by Eo, Yun-Ho Sep 5, 2022 05:55am

• Policy
• Drugs granted conditional approv to report clinical progress
• by Lee, Hye-Kyung Sep 5, 2022 05:55am

• Company
• It has been a year since the release of Leclaza
• by Chon, Seung-Hyun Sep 5, 2022 05:55am

• Policy
• MFDS has launched permission review for Pfizer Comirnaty 2
• by Kim, Jung-Ju Sep 5, 2022 05:55am

• Company
• Vyndamax is finally a step towards benefits
• by Eo, Yun-Ho Sep 2, 2022 06:03am

• Policy
• Will Migraine drug Ajovy be reimbursed following Emgality?
• by Lee, Tak-Sun Sep 2, 2022 06:03am

• Policy
• The MFDS reviews Pfizer's vaccine permission for infants
• by Lee, Hye-Kyung Sep 2, 2022 06:03am

• Company
• Q2 sales of Nexavar and Lenvima both sluggish
• by Kim, Jin-Gu Sep 2, 2022 06:03am

• Policy
• Tylenol ER, voluntarily withdrawn, will be maintained
• by Kim, Jung-Ju Sep 2, 2022 06:03am

• Company
• Japan first approved AZ Evusheld as Coronavirus tx
• by Sep 2, 2022 06:02am